^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CLU-NRG1 fusion

i
Entrez ID:
almost2years
Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinoma. (PubMed, Br J Cancer)
fPO-tailored therapy with afatinib, followed by trastuzumab and pertuzumab, successfully reduced tumour burden and blocked disease progression over a five-year period. In summary, fPO is a powerful approach for the identification of systematic drug response differences across EOC subtypes, as well as to highlight patient-specific drug regimens that could help to optimise therapies to individual patients in the future.
Journal
|
NRG1 (Neuregulin 1)
|
NRG1 fusion • CLU-NRG1 fusion • NRG1 fusion
|
Herceptin (trastuzumab) • Gilotrif (afatinib) • Perjeta (pertuzumab)
almost4years
[VIRTUAL] The HER2×HER3 bi-specific antibody Zenocutuzumab is effective at blocking growth of tumors driven by NRG1 gene fusions (AACR 2021)
Finally, we assessed the ability of Zeno to induce antibody-dependent cellular cytotoxicity using a chromium release assay and peripheral blood mononuclear cells. Zeno induced significant cytotoxicity in MDA-MB-175-VII cells while a non-ADCC enhanced, non-specific IgG had no effect.Here we show that Zeno effectively blocks the growth of NRG1 fusion-positive cell line and xenograft models of tumors arising from lung, pancreas and other organs, and these results support the continued development of Zeno to treat patients with this molecularly defined subset of cancers.
PARP Biomarker
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • NRG1 (Neuregulin 1) • CCND1 (Cyclin D1) • CD74 (CD74 Molecule) • STAT3 (Signal Transducer And Activator Of Transcription 3) • SLC3A2 (Solute Carrier Family 3 Member 2) • ATP1B1 (ATPase Na+/K+ transporting subunit beta 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
NRG1 fusion • SLC3A2-NRG1 fusion • CCND1 expression • CLU-NRG1 fusion • CDKN1B expression
|
Bizengri (zenocutuzumab-zbco)